Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (Nasdaq: CRDF) announced the dosing of the first patient in its Phase 2 ONSEMBLE trial of onvansertib, aimed at treating KRAS/NRAS-mutated metastatic colorectal cancer (mCRC). This trial seeks to demonstrate a significant improvement in treatment response when combining onvansertib with the standard of care, FOLFIRI/bevacizumab. The primary endpoint focuses on objective response rates, while secondary endpoints include progression-free survival and overall survival. The trial is being conducted at nearly half of the planned 40 sites in the U.S., showing strong interest from investigators.

Cardiff Oncology (Nasdaq: CRDF) announced the formal introduction of its Scientific Advisory Board (SAB) on March 6, 2023. The SAB consists of esteemed leaders in oncology drug development and will guide the advancement of onvansertib, the company's lead asset targeting various cancers, including metastatic colorectal and pancreatic cancers. Notable members include Dr. Scott Kopetz and Dr. Heinz-Josef Lenz, among others, who bring extensive expertise in clinical research. The SAB is expected to expand its membership to enhance expertise in new clinical indications, reinforcing Cardiff's commitment to improving cancer treatment options.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced promising Phase 1b/2 trial results for onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC), showing an objective response rate of 35%, significantly higher than historical controls. The company has a strong cash position of approximately $105.3 million as of December 31, 2022, projected to fund operations into 2025. Recent leadership appointments include Dr. Fairooz Kabbinavar as CMO, enhancing clinical expertise. Upcoming data readouts from clinical trials in mPDAC, SCLC, TNBC, and the ONSEMBLE trial are expected in 2023 and beyond, potentially advancing onvansertib's market position in oncology.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm focused on PLK1 inhibition for cancer therapies, announced its participation in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, at Boston Marriott Copley Place. Management will join a corporate panel discussion and conduct one-on-one investor meetings. The GI/GU Oncology panel discussion is scheduled for March 7 at 12:50 PM ET, with a webcast available for attendees. A replay will be accessible on the Cardiff Oncology website for 30 days post-conference.

For more details, visit Cardiff Oncology.

Cardiff Oncology (Nasdaq: CRDF) has appointed Dr. Fairooz Kabbinavar as its new chief medical officer, effective January 30, 2023. With over 30 years of experience in oncology, Dr. Kabbinavar will lead the clinical development of onvansertib, a promising treatment for colorectal cancer and other solid tumors. His prior roles include significant contributions to the approval of bevacizumab for metastatic colorectal cancer. His expertise aims to streamline Cardiff's clinical programs, particularly those targeting KRAS-mutated metastatic colorectal cancer. The Board has granted him 425,000 stock options at an exercise price of $1.75 per share.

Cardiff Oncology (Nasdaq: CRDF) will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The chat will take place on January 18 at 1:30 PM ET. Investors can register for the live webcast through the provided link. Cardiff Oncology is focused on developing therapies leveraging PLK1 inhibition to treat various cancers, including KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. For more details, visit their official website.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 3:55 PM GMT (10:55 AM ET) and will include a corporate presentation followed by a Q&A session. The company focuses on PLK1 inhibition in developing therapies for cancers such as KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. A replay will be available on their website for 90 days.